2. Academic Validation
  3. S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2

S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2

  • J Med Chem. 2022 May 12;65(9):6496-6498. doi: 10.1021/acs.jmedchem.2c00624.
Joel D A Tyndall 1
Affiliations

Affiliation

  • 1 School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.
PMID: 35507419 DOI: 10.1021/acs.jmedchem.2c00624
Abstract

The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to quickly react to the immense challenge presented to the world. The orally available 3CL Protease inhibitor S-217622 is currently progressing through clinical trials and its discovery via structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented here.

Figures
Products